Anti-Cyclic Citrullinated Peptide Antibodies
Imunidade e inflamaçãoÚltima revisão: 7 de abril de 2026. Abordagem de fontes: contexto padrão de interpretação laboratorial, material médico de referência e orientações clínicas ou de saúde pública quando relevantes.
O que é Anti-Cyclic Citrullinated Peptide Antibodies?
Anti-cyclic citrullinated peptide (anti-CCP) antibodies, also known as anti-citrullinated protein antibodies (ACPA), are autoantibodies directed against proteins that have undergone citrullination—a post-translational modification in which the amino acid arginine is converted to citrulline by peptidylarginine deiminase (PAD) enzymes. This modification can occur in many proteins including fibrinogen, vimentin, alpha-enolase, and type II collagen. In genetically susceptible individuals (particularly those carrying HLA-DRB1 shared epitope alleles), the immune system mounts a response against these citrullinated proteins, producing anti-CCP antibodies that are highly specific for rheumatoid arthritis (RA).
Anti-CCP testing has revolutionized the diagnosis of rheumatoid arthritis. The second-generation anti-CCP2 assay (the most widely used) has a specificity of 95–98% for RA, meaning a positive result is highly predictive of the disease. Anti-CCP antibodies can be detected years before the onset of clinical symptoms—up to 10 years before joint inflammation appears—making them valuable for early diagnosis. They are also a powerful prognostic marker: anti-CCP-positive RA tends to be more aggressive, with greater radiographic joint damage and erosions compared to anti-CCP-negative disease.
Por que isso importa
Anti-CCP has transformed early RA diagnosis and management. Its high specificity (95–98%) makes it far more reliable than rheumatoid factor (RF) alone, which is positive in only about 70% of RA patients and can be elevated in many other conditions. The combination of anti-CCP and RF positivity confers the highest diagnostic certainty for RA. Critically, anti-CCP positivity identifies patients at risk for more aggressive, erosive disease, enabling earlier initiation of disease-modifying antirheumatic drugs (DMARDs) before irreversible joint destruction occurs. This "window of opportunity" in early RA—where aggressive treatment can alter the disease course—makes timely anti-CCP testing clinically impactful.
Faixas de referência normais
| Grupo | Faixa | Unidade |
|---|---|---|
| Negative | <20 | U/mL |
| Weak positive | 20–39 | U/mL |
| Moderate positive | 40–59 | U/mL |
| Strong positive | ≥60 | U/mL |
As faixas de referência podem variar entre laboratórios. Sempre compare seus resultados com as faixas fornecidas pelo seu local de exame.
O que significam níveis altos de Anti-CCP
Causas comuns
- Rheumatoid arthritis (present in 60–80% of RA patients)
- Pre-clinical rheumatoid arthritis (detectable years before symptoms)
- Rarely positive in other conditions: psoriatic arthritis, SLE, Sjogren's syndrome, tuberculosis
- Smoking increases risk of developing anti-CCP antibodies in genetically susceptible individuals
Possíveis sintomas
- Anti-CCP itself does not cause symptoms
- Symmetric joint pain and swelling, particularly in small joints of hands and feet
- Morning stiffness lasting more than 30 minutes
- Fatigue
- Joint tenderness and warmth
- Rheumatoid nodules (firm bumps under the skin)
O que fazer: A positive anti-CCP in a patient with inflammatory joint symptoms strongly supports a diagnosis of RA. Rheumatology referral should be arranged promptly, ideally within 6 weeks of symptom onset. Additional workup includes rheumatoid factor, CRP, ESR, X-rays of hands and feet, and possibly musculoskeletal ultrasound or MRI. Early initiation of DMARDs (methotrexate is first-line) within the "window of opportunity" can prevent erosive disease and improve long-term outcomes. Even if symptoms are minimal, a positive anti-CCP warrants close monitoring.
O que significam níveis baixos de Anti-CCP
Causas comuns
- Negative anti-CCP is the normal result
- Seronegative rheumatoid arthritis (20–40% of RA patients are anti-CCP negative)
Possíveis sintomas
- No symptoms from a negative anti-CCP
O que fazer: A negative anti-CCP does not exclude RA—approximately 20–40% of RA patients are "seronegative." If clinical suspicion for RA remains high, the diagnosis can be made based on clinical criteria, imaging findings, and other labs. Seronegative RA generally has a somewhat better prognosis with less erosive disease, but still requires treatment with DMARDs. Musculoskeletal ultrasound can detect subclinical synovitis in seronegative patients.
Quando o exame de Anti-CCP é recomendado?
- When rheumatoid arthritis is suspected (symmetric inflammatory polyarthritis, prolonged morning stiffness)
- In conjunction with rheumatoid factor for RA diagnosis
- When differentiating RA from other forms of arthritis
- In patients with undifferentiated inflammatory arthritis to assess RA risk
- In first-degree relatives of RA patients with early joint symptoms
Perguntas frequentes
Biomarcadores relacionados
Referências e abordagem de revisão
As páginas do glossário de biomarcadores são explicações educativas e devem ser interpretadas junto com as faixas de referência e observações fornecidas pelo seu laboratório e pelo seu médico. Para conhecer nossos padrões editoriais e processo de revisão, veja nossa Política editorial e a nossa revisão de conteúdo.
Quer analisar seus níveis de Anti-CCP?
Envie seus resultados de exames para receber uma análise instantânea com IA de todos os seus biomarcadores.
Enviar resultados de exames →Aviso médico: Estas informações são apenas educativas e não substituem orientação, diagnóstico ou tratamento médico profissional. As faixas de referência podem variar entre laboratórios. Sempre converse com seu profissional de saúde sobre a interpretação dos seus resultados específicos.